Table 4.

Response to induction therapy according to cytogenetic abnormalities

Cytogenetic abnormality
No. of patients
CR, %
95% CI
ED/HD, %
RD, %
Normal karyotype   161   52   44-60   11   37  
Unbalanced*      
    +4   5   40   11-77   20   40  
    -5/del(5q)   54   7   3-18   26   67  
        -5   16   0   0-19   38   63  
        del(5q)   38   11   5-27   21   68  
        -7/del(7q)   49   6   2-17   18   76  
        -7   22   9   3-28   18   73  
        del(7q)   27   4   0-20   19   78  
    +8   38   32   19-47   26   42  
        Noncomplex   19   53   32-73   16   32  
        Complex   19   11   3-31   37   53  
    +11   20   30   12-49   30   40  
        Noncomplex   6   83   38-99   0   17  
        Complex   14   7   0-31   43   50  
    +13   17   18   6-41   24   59  
    del(13q)   14   0   0-22   21   79  
    +14   9   22   6-55   22   56  
    -17/del(17p)   24   4   0-20   29   67  
        -17   14   0   0-22   21   79  
        del(17p)   9   11   0-43   33   56  
    -18   9   0   0-30   33   67  
    -20/del(20q)   19   0   0-17   21   79  
        -20   7   0   0-35   29   71  
        del(20q)   12   0   0-24   17   83  
    +21   16   19   7-43   13   69  
    +22   14   14   4-40   14   71  
Balanced†      
    t(8;21)   12   58   32-81   17   25  
    t(11q23)   11   55   28-79   18   27  
    t(15;17)   11   73   43-90   27   0  
    inv(16)/t(16;16)   14   86   60-96   14   0  
Other‡      
    abn(3q)   14   0   0-22   14   86  
    abn(12p)   22   18   7-39   23   59  
Complex      
    3 or more unrelated   61   10   5-20   28   62  
    5 or more unrelated   44   7   2-18   25   68  
All patients
 		 861
 		 43
 		 38-48
 		 14
 		 43
 
Cytogenetic abnormality
No. of patients
CR, %
95% CI
ED/HD, %
RD, %
Normal karyotype   161   52   44-60   11   37  
Unbalanced*      
    +4   5   40   11-77   20   40  
    -5/del(5q)   54   7   3-18   26   67  
        -5   16   0   0-19   38   63  
        del(5q)   38   11   5-27   21   68  
        -7/del(7q)   49   6   2-17   18   76  
        -7   22   9   3-28   18   73  
        del(7q)   27   4   0-20   19   78  
    +8   38   32   19-47   26   42  
        Noncomplex   19   53   32-73   16   32  
        Complex   19   11   3-31   37   53  
    +11   20   30   12-49   30   40  
        Noncomplex   6   83   38-99   0   17  
        Complex   14   7   0-31   43   50  
    +13   17   18   6-41   24   59  
    del(13q)   14   0   0-22   21   79  
    +14   9   22   6-55   22   56  
    -17/del(17p)   24   4   0-20   29   67  
        -17   14   0   0-22   21   79  
        del(17p)   9   11   0-43   33   56  
    -18   9   0   0-30   33   67  
    -20/del(20q)   19   0   0-17   21   79  
        -20   7   0   0-35   29   71  
        del(20q)   12   0   0-24   17   83  
    +21   16   19   7-43   13   69  
    +22   14   14   4-40   14   71  
Balanced†      
    t(8;21)   12   58   32-81   17   25  
    t(11q23)   11   55   28-79   18   27  
    t(15;17)   11   73   43-90   27   0  
    inv(16)/t(16;16)   14   86   60-96   14   0  
Other‡      
    abn(3q)   14   0   0-22   14   86  
    abn(12p)   22   18   7-39   23   59  
Complex      
    3 or more unrelated   61   10   5-20   28   62  
    5 or more unrelated   44   7   2-18   25   68  
All patients
 		 861
 		 43
 		 38-48
 		 14
 		 43
 

Patients may be counted more than once due to the coexistence of more than 1 cytogenetic abnormality in the leukemic clone. Percentages may not add to 100 because of rounding.

*

In the absence of t(8;21), t(11q23), t(15;17), or inv(16)/t(16;16).

†

Irrespective of karyotype complexity.

‡

Including cases with unbalanced or balanced abnormalities.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal